Literature DB >> 29258786

Genetic and immune determinants of immune activation in HIV-exposed seronegative individuals and their role in protection against HIV infection.

Claudio Fenizia1, Jean-François Rossignol2, Mario Clerici3, Mara Biasin4.   

Abstract

Soon thereafter infection is established, hosts strive for an efficient eradication of microorganisms, with as limited tissue damage as possible, and durable immunological protection against re-infection. On the other hand, pathogens have developed countermeasures to escape host surveillance and to warrant diffusion to other hosts. In this molecular arms race the final results relies on multiple variables, including the genetic and immunologic e correlates of protection available for the host. In the field of HIV-infection, natural protection has been repeatedly associated to the presence of an immune activation state, at least in some cohorts of HESN (HIV-exposed seronegative). Indeed, these subjects, who naturally resist HIV-infection despite repeated exposure to the virus, are characterized by an increased expression of activation markers on circulating cells and greater production of immunological effector molecules both in basal condition and upon specific-stimulation. Although these results are not univocally shared, several publications emphasize the existence of a correlation between polymorphisms in genes associated with increased immune activation and the HESN phenotype. In this review, we will describe some of the genetic variants associated with protection against HIV infection. Understanding the basis of HIV resistance in HESN is mandatory to develop new preventative and therapeutic interventions.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HESN; HIV; Immune activation; Polymorphisms; Resistance

Mesh:

Substances:

Year:  2017        PMID: 29258786     DOI: 10.1016/j.meegid.2017.12.014

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  5 in total

1.  ERAPs Reduce In Vitro HIV Infection by Activating Innate Immune Response.

Authors:  Irma Saulle; Ivana Marventano; Marina Saresella; Claudia Vanetti; Micaela Garziano; Claudio Fenizia; Daria Trabattoni; Mario Clerici; Mara Biasin
Journal:  J Immunol       Date:  2021-02-22       Impact factor: 5.422

2.  CD46 Genetic Variability and HIV-1 Infection Susceptibility.

Authors:  Carmen Serrano-Rísquez; Mohamed Omar; María Amparo Gómez-Vidal; Luis Miguel Real; Juan Antonio Pineda; Antonio Rivero; Antonio Rivero-Juárez; Donald Forthal; Francisco J Márquez; Sergio Lo Caputo; Mario Clerici; Mara Biasin; Antonio Caruz
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600

3.  The Modulation of Cholesterol Metabolism Is Involved in the Antiviral Effect of Nitazoxanide.

Authors:  Claudio Fenizia; Salomè Valentina Ibba; Claudia Vanetti; Sergio Strizzi; Jean-François Rossignol; Mara Biasin; Daria Trabattoni; Mario Clerici
Journal:  Infect Dis Rep       Date:  2021-07-14

4.  Endoplasmic Reticulum Associated Aminopeptidase 2 (ERAP2) Is Released in the Secretome of Activated MDMs and Reduces in vitro HIV-1 Infection.

Authors:  Irma Saulle; Salomè Valentina Ibba; Enrica Torretta; Cecilia Vittori; Claudio Fenizia; Federica Piancone; Davide Minisci; Elisa Maria Lori; Daria Trabattoni; Cecilia Gelfi; Mario Clerici; Mara Biasin
Journal:  Front Immunol       Date:  2019-07-16       Impact factor: 7.561

Review 5.  The Importance of Regulation in Natural Immunity to HIV.

Authors:  Laurence Blondin-Ladrie; Matheus Aranguren; Kim Doyon-Laliberté; Johanne Poudrier; Michel Roger
Journal:  Vaccines (Basel)       Date:  2021-03-18
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.